Epizyme Inc

-0.04 (-0.90%)
4:35:55 PM EDT: $4.30 -0.09 (-2.05%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)448.89M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.36 Million
Adjusted EPS-$0.49
See more estimates
10-Day MA$4.58
50-Day MA$5.10
200-Day MA$7.80
See more pivots

Epizyme Inc Stock, NASDAQ:EPZM

400 Technology Square, 4th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.229.5872
Number of Employees: 304


Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.